Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI)

Completed · Phase 4

Conditions studied: Pancreatic Cancer

In brief

The purpose of this research study is to see if a specific kind of MRI, called Ultrasmall Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI), which uses an FDA-approved therapeutic agent(Feraheme) to see if it is able to identify small and otherwise undetectable lymph node metastases in people who have pancreatic cancer and are scheduled for surgical resection.

Key facts

Study ID

NCT00920023

Run by

Massachusetts General Hospital

People needed

35

Starts

2008-07-01

Expected to finish

2013-02-01

Last updated by the study team

2017-07-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Locally resectable pancreatic mass present on one or more pre-operative imaging modalities
• Must demonstrate no evidence of distant metastases as assessed by chest/abdomen/pelvis CT scan
• Deemed eligible for resection with curative intent by a treating surgeon who is listed as an investigator on this study
• 18 years of age or older
• No uncontrolled serious medical or psychiatric illness
• Women of childbearing potential must not be pregnant or lactating

You may not qualify if…

• Known allergy to iron or dextran
• Pregnant or lactating
• Counter-indication to MRI, such as the presence of metallic prostheses or implanted metal device
• Sickle cell disease or hemoglobinopathy

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.